Drug intelligence / Profile preview

BMN 290

Development stage: Discontinued
Lead developer: BioMarin
Modality: Small Molecules

Overview

BMN 290 is a selective chromatin modulation therapy, specifically a histone deacetylase inhibitor, designed to increase frataxin expression. It is being developed for the treatment of Friedreich's ataxia (FA), a rare autosomal recessive disorder causing progressive neurological and cardiac decline.

Targets

HDAC (HDAC family)

Beyond the preview

Go deeper on BMN 290.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMN 290.

Explore the full profile